Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency

FDA approved avatrombopag for thrombocytopenia in CLD patients scheduled for a procedure

/1 Comment/in /by

 

You might also like
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FoundationOne companion diagnostic FDA approved
Trifluridine/tipiracil combination FDA approved for metastatic gastric or GEJ adenocarcinoma
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Frontline nivolumab plus ipilimumab approved for intermediate or poor risk advanced RCC
FDA approved nilotinib for paediatric patients with newly diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI
us-fda-approval-medipaper-medical-communications-agency-medical-writer-agency-apac-asia-pacific-HK-hong-kong-oncology-CV-neurology-immunotherapy-obesity-diabetes-specialty-infectious.jpg Discontinuation, post-discontinuation monitoring criteria, and guidance for treatment re-initiation in patients taking nilotinib for Ph+ CML with a sustained molecular response
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency Alectinib FDA approved for ALK-positive metastatic NSCLC
Glasdegib plus low-dose cytarabine (LDAC) approved in elderly AML patients
Ribociclib FDA label updated to include pre- and perimenopausal women©United States Food and Drug Agency FDA approved biosimilar pegfilgrastim to decrease the chance of febrile neutropenia in patients with non-myeloid cancers on myelosuppressive chemotherapy
1 reply

Trackbacks & Pingbacks

  1. FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure - MediNews Asia says:
    23rd May 2018 at 11:47 PM

    […] post FDA approved avatrombopag for thrombocytopenia in CLD patient scheduled for a procedure appeared first on Medical Writer Agency | 香港醫學作家 | MediPR | MediPaper Hong […]

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply